Skip to main content
. 2022 Apr 14;9:847091. doi: 10.3389/fmed.2022.847091

TABLE 4.

Clinical characteristics stratified by HDLC in patients with DM.

Before propensity score matching
After propensity score matching
Low HDLC group (n = 59) Normal HDLC group (n = 41) p-value Low HDLC group (n = 40) Normal HDLC group (n = 31) p-value
Sex 0.657 1.000
Male 41 (69.5) 31 (75.6) 28 (70.0) 22 (71.0)
Female 18 (30.5) 10 (24.4) 13 (30.0) 9 (29.0)
Age, years 0.068 0.600
≥60 21 (35.6) 23 (56.1) 17 (42.5) 16 (51.6)
<60 38 (64.4) 18 (43.9) 23 (57.5) 15 (48.4)
BMI, kg/m2 0.043 0.398
≥24.0 32 (54.2) 13 (31.7) 18 (45.0) 10 (32.3)
<24.0 27 (45.8) 28 (68.3) 22 (55.0) 21 (67.7)
Extra-hepatic disease 1.000 0.991
Present 19 (32.2) 14 (34.1) 13 (32.5) 11 (35.5)
Absent 40 (67.8) 27 (65.9) 27 (67.5) 20 (64.5)
Hepatocellular carcinoma 0.068 0.497
Present 17 (28.8) 20 (50.0) 15 (37.5) 15 (48.4)
Absent 42 (71.2) 20 (50.0) 25 (62.5) 16 (51.2)
Triglycerides, mmol/L 0.466* 1.000*
High 6 (10.2) 2 (4.9) 2 (5.0) 1 (3.2)
Normal 53 (89.8) 39 (95.1) 38 (95.0) 30 (96.8)
ALT, IU/L 0.055 0.996
≥2-fold normal upper limit 13 (22.0) 3 (9.8) 4 (10.00) 3 (9.7)
0–2-fold normal upper limit 13 (22.0) 6 (17.1) 8 (20.0) 6 (19.4)
Normal 33 (55.9) 32 (73.2) 28 (7) 22 (71.0)
AST, IU/L 0.038 0.972
≥2-fold normal upper limit 16 (27.1) 4 (9.8) 5 (12.5) 4 (12.9)
0–2-fold normal upper limit 14 (23.7) 7 (17.1) 10 (25.0) 7 (22.6)
Normal 29 (49.2) 30 (73.2) 25 (62.5) 20 (64.5)
MELD score 0.005 0.233
Median 9.0 6.0 8.0 6.0
Interquartile range 5–14 4–9 5–12 4–10
Infection 0.002 0.018
Present 22 (18.3) 3 (7.3) 13 (32.5) 2 (6.5)
Absent 37 (81.1) 38 (92.7) 27 (67.5) 29 (93.5)

Data are presented as the number with percentage or median with interquartile range. ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; DM, diabetes mellitus; HDLC, high-density lipoprotein cholesterol; MELD, model for end-stage liver disease. *Represents Fisher’s exact test.